期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 23, 期 5, 页码 953-959出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2015.01.022
关键词
BRD4; Bromodomain; Benzoyladenine; Structure-activity relationship
资金
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Japan Society for the Promotion of Science
- Grants-in-Aid for Scientific Research [26293025, 26810091] Funding Source: KAKEN
Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that bind to acetylated lysines in histones. Among them, BRD4 is a candidate target molecule of therapeutic agents for diverse diseases, including cancer and inflammatory disease. As a part of our continuing structural development studies of thalidomide to obtain a broad spectrum of biological modifiers based on the 'multi-template' approach, in this work we focused on BRD4-inhibitory activity, and discovered that N6-benzoyladenine derivatives exhibit this activity. Structure-activity relationship studies led to N6-(2,4,5-trimethoxybenzoyl) adenine (29), which exhibits potent BRD4 bromodomain1 inhibitory activity with an IC50 value of 0.427 mu M. N6-Benzoyladenine appears to be a new chemical scaffold for development of BRD4 inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据